+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Computer-Aided Drug Discovery Market - Forecasts from 2025 to 2030

  • PDF Icon

    Report

  • 140 Pages
  • January 2025
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 6050599
The computer-aided drug discovery market is projected to grow at a CAGR of 11.59% over the forecast period, increasing from US$5.955 billion in 2025 to US$10.306 billion by 2030.

Drug discovery is a lengthy and complex process, but digital transformation is enhancing efficiency and effectiveness in the pharmaceutical industry. The integration of computer-aided drug discovery, automation, and digitization has become essential for improving quality, reducing costs, and shortening timelines. As resource constraints and changing scenarios arise, automation and digitization are key drivers of business growth. The application of quantum mechanics in computer-aided drug discovery has enabled highly accurate in-silico modeling of biological and chemical systems, facilitating the identification of novel drug candidates. The rising incidence of chronic diseases has intensified the need for rapid drug development, further boosting the growth of the computer-aided drug discovery market. According to the National Center for Health Statistics, it is projected that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023, underscoring the urgency of addressing these health challenges.

Drivers of the Computer-Aided Drug Discovery Market:

  • Expanding Use of Artificial Intelligence in Drug Discovery: The complexity and time-consuming nature of new drug discovery necessitate advanced solutions. Identifying suitable compounds that can effectively bind to specific disease-related targets requires screening vast numbers of molecules. AI is transforming this process by enabling the discovery of potential compounds through technologies such as knowledge graphs, in-silico target identification, and target ranking, which expedite treatment development with greater precision.
For instance, in December 2023, Merck launched AIDDISON, a groundbreaking drug discovery software platform that integrates generative AI, machine learning, and computer-aided drug design. This software bridges the gap between virtual molecule design and real-world manufacturability through Synthia™ retrosynthesis API integration. AIDDISON analyzes over 60 billion possibilities based on key properties essential for successful drugs - such as non-toxicity, solubility, and stability - drawing on more than two decades of validated datasets from pharmaceutical R&D.AI and machine learning models like AIDDISON significantly enhance the success rate of new patient therapies while potentially reducing costs associated with drug discovery by up to 70%.

Geographical Trends Shaping the Computer-Aided Drug Discovery Market:

  • Significant Growth in North America: The computer-aided drug discovery market is poised for substantial growth in the United States due to several factors, including a rising prevalence of mental health disorders, advancements in AI technologies, and increasing acceptance of telehealth solutions. The demand for effective treatment options for mental health issues such as anxiety, depression, and PTSD has surged since the COVID-19 pandemic exacerbated these challenges.
As traditional healthcare systems struggle to keep up with demand, AI technologies are emerging as viable solutions to provide scalable and accessible mental health care. AI-driven platforms can analyze large datasets to offer personalized therapy and real-time emotional support. The U.S. government has recognized AI's potential in healthcare and has initiated programs to promote its development. For example, the American AI Initiative aims to position the U.S. as a leader in artificial intelligence by establishing guidelines for its application across various sectors. Additionally, favorable funding opportunities for mental health technology have attracted investments from both public and private sectors. The combination of a robust healthcare IT infrastructure and growing public awareness about mental health issues creates an environment conducive to rapid expansion of AI solutions. In summary, the computer-aided drug discovery market is set for significant growth driven by increased adoption of AI applications in drug discovery processes, rising global demand for effective treatments for chronic diseases, supportive governmental initiatives promoting innovation in healthcare technologies, and favorable geographical trends - especially within North America - that enhance this expanding market landscape.

Reasons for buying this report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence.

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Computer-Aided Drug Discovery Market has been segmented as following:

  • By Type
    • Structure-Based Drug Design
    • Ligand-Based Drug Design
    • Sequence-Based Approaches
  • By Therapeutic Area
    • Oncology
    • Neurology
    • Cardiovascular Disease
    • Respiratory Disease
    • Others
  • By End User
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Research Laboratories
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Rest of the Middle East and Africa
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Rest of Asia-Pacific

Table of Contents

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
2.3. Data Validation
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Supplier
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. COMPUTER-AIDED DRUG DISCOVERY MARKET BY TYPE
5.1. Introduction
5.2. Structure-Based Drug Design
5.3. Ligand-Based Drug Design
5.4. Sequence-Based Approaches
6. COMPUTER-AIDED DRUG DISCOVERY MARKET BY THERAPEUTIC AREA
6.1. Introduction
6.2. Oncology
6.3. Neurology
6.4. Cardiovascular Disease
6.5. Respiratory Disease
6.6. Others
7. COMPUTER-AIDED DRUG DISCOVERY MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceutical Companies
7.3. Biotechnology Companies
7.4. Research Laboratories
8. COMPUTER-AIDED DRUG DISCOVERY MARKET BY GEOGRAPHY
8.1. Global Overview
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Rest of South America
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Rest of Europe
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. United Arab Emirates
8.5.3. Rest of the Middle East and Africa
8.6. Asia-Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Rest of Asia-Pacific
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Aragen Life Sciences Pvt. Ltd.
10.2. Bioduro-Sundia
10.3. BOC Sciences
10.4. Aris Pharmaceuticals, Inc.
10.5. AstraZeneca
10.6. Schrödinger, Inc.
10.7. Bayer AG
10.8. Charles River Laboratories
10.9. Albany Molecular Research Inc. (Curia Global, Inc.)
10.10. Insilico Medicine

Companies Mentioned

  • Aragen Life Sciences Pvt. Ltd.
  • Bioduro-Sundia
  • BOC Sciences
  • Aris Pharmaceuticals, Inc.
  • AstraZeneca
  • Schrödinger, Inc.
  • Bayer AG
  • Charles River Laboratories
  • Albany Molecular Research Inc. (Curia Global, Inc.)
  • Insilico Medicine

Methodology

Loading
LOADING...

Table Information